CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗肺癌
英文原题：CAR-T Cells for the Treatment of Lung Cancer.
查看英文原题
CAR-T Cells for the Treatment of Lung Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
表达嵌合抗原受体（CAR-T）的基因修饰T淋巴细胞过继细胞疗法是治疗癌症最有前景的先进疗法之一，在血液系统恶性肿瘤中取得了前所未有的疗效。然而，CAR-T 细胞在实体瘤中的疗效仍非常不理想，因为强大的免疫抑制性肿瘤微环境阻碍了免疫应答。开发针对实体瘤的下一代个性化CAR-T 细胞是临床的迫切需求。为新CAR-T 疗法确定治疗靶点以提高在实体瘤中的疗效、生存期、持久性和安全性，仍然是癌症免疫治疗的关键前沿。在此，我们总结了CAR-T 细胞免疫疗法在肺癌中的基础、转化和临床结果，从其分子工程和机制研究到临床前和临床开发。
展开英文摘要原文
Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies.
However, the efficacy of CAR-T cells in solid tumors is still very unsatisfactory, because of the strong immunosuppressive tumor microenvironment that hinders immune responses. The development of next-generation personalized CAR-T cells against solid tumors is a clinical necessity. The identification of therapeutic targets for new CAR-T therapies to increase the efficacy, survival, persistence, and safety in solid tumors remains a critical frontier in cancer immunotherapy.
Here, we summarize basic, translational, and clinical results of CAR-T cell immunotherapies in lung cancer, from their molecular engineering and mechanistic studies to preclinical and clinical development.
论文信息
- 作者
- Chocarro L、Arasanz H、Fernández-Rubio L、Blanco E、Echaide M、Bocanegra A、Teijeira L、Garnica M
- 单位
- Oncoimmunology Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.Spain
- 文献类型
- 综述
- 期刊
- Life (Basel, Switzerland)2022 Apr 8
- 原文标识
- PubMed 35455052 · DOI 10.3390/life12040561
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →